These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 20453068)
21. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624 [TBL] [Abstract][Full Text] [Related]
22. Helicase-primase complex of herpes simplex virus type 1: a mutation in the UL52 subunit abolishes primase activity. Klinedinst DK; Challberg MD J Virol; 1994 Jun; 68(6):3693-701. PubMed ID: 8189507 [TBL] [Abstract][Full Text] [Related]
23. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1. Biswas S; Swift M; Field HJ Antivir Chem Chemother; 2007; 18(1):13-23. PubMed ID: 17354648 [TBL] [Abstract][Full Text] [Related]
24. The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase. Andrei G; Gillemot S; Topalis D; Snoeck R J Infect Dis; 2018 Feb; 217(5):790-801. PubMed ID: 29186456 [TBL] [Abstract][Full Text] [Related]
25. A mutation in the human herpes simplex virus type 1 UL52 zinc finger motif results in defective primase activity but can recruit viral polymerase and support viral replication efficiently. Chen Y; Livingston CM; Carrington-Lawrence SD; Bai P; Weller SK J Virol; 2007 Aug; 81(16):8742-51. PubMed ID: 17553899 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection. Katsumata K; Chono K; Kato K; Ohtsu Y; Takakura S; Kontani T; Suzuki H Antimicrob Agents Chemother; 2013 Mar; 57(3):1339-46. PubMed ID: 23274658 [TBL] [Abstract][Full Text] [Related]
27. Antiviral activity of PHA767491 against human herpes simplex virus in vitro and in vivo. Hou J; Zhang Z; Huang Q; Yan J; Zhang X; Yu X; Tan G; Zheng C; Xu F; He S BMC Infect Dis; 2017 Mar; 17(1):217. PubMed ID: 28320320 [TBL] [Abstract][Full Text] [Related]
28. Phenotypic and genotypic characterization of induced acyclovir-resistant clinical isolates of herpes simplex virus type 1. Hussin A; Md Nor NS; Ibrahim N Antiviral Res; 2013 Nov; 100(2):306-13. PubMed ID: 24055837 [TBL] [Abstract][Full Text] [Related]
29. No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy. Edlefsen PT; Birkmann A; Huang ML; Magaret CA; Kee JJ; Diem K; Goldner T; Timmler B; Stoelben S; Ruebsamen-Schaeff H; Zimmermann H; Warren T; Wald A; Corey L J Infect Dis; 2016 Jul; 214(2):258-64. PubMed ID: 27056950 [TBL] [Abstract][Full Text] [Related]
30. The two helicases of herpes simplex virus type 1 (HSV-1). Chattopadhyay S; Chen Y; Weller SK Front Biosci; 2006 Sep; 11():2213-23. PubMed ID: 16720308 [TBL] [Abstract][Full Text] [Related]
31. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor. Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917 [TBL] [Abstract][Full Text] [Related]
32. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1. Duan J; Liuzzi M; Paris W; Liard F; Browne A; Dansereau N; Simoneau B; Faucher AM; Cordingley MG Antimicrob Agents Chemother; 2003 Jun; 47(6):1798-804. PubMed ID: 12760851 [TBL] [Abstract][Full Text] [Related]
33. Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections. Biswas S; Sukla S; Field HJ Future Med Chem; 2014 Jan; 6(1):45-55. PubMed ID: 24358947 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model. Biswas S; Sukla S; Goldner T; Field HJ; Kropeit D; Paulsen D; Welbers A; Ruebsamen-Schaeff H; Zimmermann H; Birkmann A Antimicrob Agents Chemother; 2014 Jul; 58(7):3843-52. PubMed ID: 24752278 [TBL] [Abstract][Full Text] [Related]
35. The UL8 component of the herpes simplex virus helicase-primase complex stimulates primer synthesis by a subassembly of the UL5 and UL52 components. Tenney DJ; Hurlburt WW; Micheletti PA; Bifano M; Hamatake RK J Biol Chem; 1994 Feb; 269(7):5030-5. PubMed ID: 8106478 [TBL] [Abstract][Full Text] [Related]
36. Surveillance of herpes simplex virus resistance to antivirals: a 4-year survey. Burrel S; Aime C; Hermet L; Ait-Arkoub Z; Agut H; Boutolleau D Antiviral Res; 2013 Nov; 100(2):365-72. PubMed ID: 24075863 [TBL] [Abstract][Full Text] [Related]